Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA Gastric-204
jRCT2031250741Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) comparing Pumitamig plus Chemotherapy with Nivolumab plus Chemotherapy (2 arms). Primary endpoints: Objective Response, Progression-Free Survival and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
pumitamignivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031250741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250741.